- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
MSLN antibody recognizes Mesothelin, a glycosylphosphatidylinositol-anchored cell surface glycoprotein encoded by the MSLN gene located on chromosome 16p13.3. MSLN Antibody for IHC is optimized to detect Mesothelin expression in formalin-fixed, paraffin-embedded tissues used in cancer research. Mesothelin is synthesized as a precursor protein that undergoes furin-mediated cleavage to generate a membrane-bound mature form and a secreted fragment known as megakaryocyte potentiating factor. In normal tissues, Mesothelin expression is largely restricted to mesothelial cells lining the pleura, peritoneum, and pericardium, where it localizes primarily to the plasma membrane.
Mesothelin antibody, also referred to in the literature as CAK1 antibody and megakaryocyte potentiating factor precursor antibody, targets a differentiation antigen that is markedly overexpressed in malignant mesothelioma, pancreatic ductal adenocarcinoma, ovarian serous carcinoma, and subsets of lung and gastric carcinomas. In tumor samples, Mesothelin typically demonstrates strong membranous staining with variable cytoplasmic signal reflecting intracellular synthesis and trafficking prior to surface anchoring. Its limited distribution in most normal tissues combined with significant upregulation in cancer has established Mesothelin as a widely studied tumor biomarker in histopathologic evaluation.
Functionally, Mesothelin contributes to tumor cell adhesion and metastatic dissemination. A well-characterized interaction occurs between Mesothelin and MUC16, also known as CA125, facilitating heterotypic adhesion that may promote peritoneal implantation and spread of ovarian carcinoma cells. Mesothelin expression has also been associated with enhanced proliferative capacity, resistance to apoptosis, and activation of signaling pathways that support tumor progression. Although its exact physiologic role in normal mesothelial biology remains incompletely defined, its involvement in oncogenic processes is well documented.
The MSLN gene product undergoes post-translational processing and may generate soluble Mesothelin-related peptides detectable in patient serum. These circulating forms have been investigated as research biomarkers, particularly in mesothelioma and pancreatic cancer. Due to its cell surface accessibility and tumor-restricted distribution pattern, Mesothelin remains a prominent target in translational oncology research and therapeutic development.
This mouse monoclonal antibody clone MSVA-235M targets Mesothelin for research applications focused on tissue-based detection and biomarker assessment. By enabling clear visualization of Mesothelin expression patterns in relevant specimens, this Mesothelin antibody supports cancer research efforts at NSJ Bioreagents.
1. Optimal dilution of the MSLN Antibody for IHC should be determined by the researcher.
2. Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121oC in pH 7.8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:150 at 37oC for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer's directions.
A recombinant fragment (around amino acids 273-407) of human Mesothelin (MSLN) protein (exact sequence is proprietary) was used as the immuongen for the MSLN/Mesothelin antibody.
MSLN Antibody for IHC with sodium azide - store at 2 to 8oC; antibody without sodium azide - store at -20 to -80oC.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.